Vitamin C selectively eliminates erlotinib-induced drug-tolerant persister cells via CERK and KRT82 regulation in EGFR-mutant non-small cell lung cancer
Despite the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib in EGFR -mutant non-small cell lung cancer (NSCLC) patients, a subset of drug-tolerant persister (DTP) cells remains. While protein alterations unique to DTPs are crucial for their survival, the mechanisms re...